THERAPY DOSSIER · th-585e6ddc9d5b

Acanthopanax (Eleutherococcus) plant extract, compared with ulinastatin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03210519 ↗NAcompleted

Eleutherococcus senticosus for Anti-inflammation and EPO Hyporesponsiveness in Renal Dialysis

Renal Dialysis

Enrolment: 21 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25533505 ↗2014Reported benefit

Protective effects of Acanthopanax vs. Ulinastatin against severe acute pancreatitis-induced brain injury in rats.

RatOtherSprague-DawleyMale

Model: Surgically induced severe acute pancreatitis with secondary brain injury; sham operation as negative control

Both acanthopanax and ulinastatin lowered mortality, pro-inflammatory cytokines, NF-kappaB p65 activity and pancreatic and brain pathology scores relative to the untreated model, with no significant difference between the two treatments.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…